Overview

Evant is a veterinary vaccine used to protect chickens against coccidiosis caused by the coccidia parasites Eimeria acervulina, Eimeria maxima, Eimeria mitis, Eimeria praecox and Eimeria tenella. Coccidiosis is a disease of the gut which results in reduced growth, severe diarrhoea, reduced egg production and a high death rate. Infected birds shed disease spores (oocysts) in their faeces that can spread the infection.

The vaccine contains live attenuated (weakened) oocysts of Eimeria acervulina, Eimeria maxima, Eimeria mitis, Eimeria praecox and Eimeria tenella.

For more information, see the package leaflet.

Evant is available as a suspension and solvent and can only be obtained with a prescription. The vaccine is given to chicks from one day old. The vaccine suspension should be diluted with the solvent and water according to dosing instructions and sprayed on the birds so that each bird receives one dose. The birds ingest the vaccine when preening their feathers. Protection starts at 2 weeks after vaccination and lasts until 9 weeks after vaccination.

For more information about using Evant, see the package leaflet or contact your veterinarian or pharmacist.

Evant is a vaccine. Vaccines work by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease. The vaccine contains the oocysts of Eimeria species that have been weakened so that they cannot cause disease. When Evant is given to chickens, the animals’ immune system recognises the Eimeria oocysts as foreign and makes defences against them. In the future if the animals are exposed to the same Eimeria species the immune system will be able to respond more quickly. This will help protect against coccidiosis.

The vaccine solvent contains the adjuvant montanide IMS to enhance the immune response.

Laboratory studies have shown that 1-day-old chicks vaccinated with Evant were protected against coccidiosis when exposed to each of the five Eimeria species at 2 weeks after vaccination and protection lasted 9 weeks after vaccination. These studies had a control group of chicks that received a dummy vaccination. The studies showed Evant reduced damage to the gut and oocysts in the faeces for each Eimeria species and that it reduced diarrhoea caused by Emeria acervulina, Eimeria maxima and Eimeria tenella.

There are no known side effects with Evant. For the full list of restrictions, see the package leaflet.

Safety information has been included in the summary of product characteristics and the package leaflet for Evant, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.

Hands and equipment should be washed and disinfected after use.

The withdrawal period is the time required after administration of a medicine before an animal can be slaughtered and the meat used for human consumption. It is also the time required after administration of a medicine before eggs may be used for human consumption.

The withdrawal period for meat and eggs from chickens treated with Evant is ‘zero’ days, which means that there is no mandatory waiting time.

The European Medicines Agency decided that Evant’s benefits are greater than its risks and it can be authorised for use in the EU.

Evant received a marketing authorisation valid throughout the EU on 5 February 2019.

български (BG) (109.32 KB - PDF)

View

español (ES) (76.56 KB - PDF)

View

čeština (CS) (105.22 KB - PDF)

View

dansk (DA) (75.81 KB - PDF)

View

Deutsch (DE) (77.4 KB - PDF)

View

eesti keel (ET) (75.77 KB - PDF)

View

ελληνικά (EL) (111.65 KB - PDF)

View

français (FR) (77.21 KB - PDF)

View

hrvatski (HR) (93.68 KB - PDF)

View

italiano (IT) (76.27 KB - PDF)

View

latviešu valoda (LV) (104.34 KB - PDF)

View

lietuvių kalba (LT) (97.43 KB - PDF)

View

magyar (HU) (101.98 KB - PDF)

View

Malti (MT) (107.12 KB - PDF)

View

Nederlands (NL) (76.39 KB - PDF)

View

polski (PL) (107.11 KB - PDF)

View

português (PT) (76.63 KB - PDF)

View

română (RO) (96.05 KB - PDF)

View

slovenčina (SK) (106.72 KB - PDF)

View

slovenščina (SL) (89.68 KB - PDF)

View

Suomi (FI) (81.53 KB - PDF)

View

svenska (SV) (76.38 KB - PDF)

View

Product information

български (BG) (236.23 KB - PDF)

View

español (ES) (146.22 KB - PDF)

View

čeština (CS) (203.88 KB - PDF)

View

dansk (DA) (147.69 KB - PDF)

View

Deutsch (DE) (180.22 KB - PDF)

View

eesti keel (ET) (156.02 KB - PDF)

View

ελληνικά (EL) (223.72 KB - PDF)

View

français (FR) (152.57 KB - PDF)

View

hrvatski (HR) (194 KB - PDF)

View

íslenska (IS) (144.84 KB - PDF)

View

italiano (IT) (152.56 KB - PDF)

View

latviešu valoda (LV) (205.09 KB - PDF)

View

lietuvių kalba (LT) (200.8 KB - PDF)

View

magyar (HU) (195.26 KB - PDF)

View

Malti (MT) (220.17 KB - PDF)

View

Nederlands (NL) (153.7 KB - PDF)

View

norsk (NO) (199.94 KB - PDF)

View

polski (PL) (214.89 KB - PDF)

View

português (PT) (154.1 KB - PDF)

View

română (RO) (200.61 KB - PDF)

View

slovenčina (SK) (213.33 KB - PDF)

View

slovenščina (SL) (191.6 KB - PDF)

View

Suomi (FI) (168.38 KB - PDF)

View

svenska (SV) (154.02 KB - PDF)

View

Latest procedure affecting product information: II/002/G

19/01/2022

български (BG) (109.14 KB - PDF)

View

español (ES) (86.92 KB - PDF)

View

čeština (CS) (116.46 KB - PDF)

View

dansk (DA) (88.62 KB - PDF)

View

Deutsch (DE) (94.33 KB - PDF)

View

eesti keel (ET) (88.61 KB - PDF)

View

ελληνικά (EL) (116.02 KB - PDF)

View

français (FR) (87.86 KB - PDF)

View

hrvatski (HR) (117.79 KB - PDF)

View

íslenska (IS) (88.34 KB - PDF)

View

italiano (IT) (86.45 KB - PDF)

View

latviešu valoda (LV) (106.93 KB - PDF)

View

lietuvių kalba (LT) (126.34 KB - PDF)

View

magyar (HU) (115.8 KB - PDF)

View

Malti (MT) (110.73 KB - PDF)

View

Nederlands (NL) (88.34 KB - PDF)

View

norsk (NO) (88.61 KB - PDF)

View

polski (PL) (110.19 KB - PDF)

View

português (PT) (87.75 KB - PDF)

View

română (RO) (100.76 KB - PDF)

View

slovenčina (SK) (101.25 KB - PDF)

View

slovenščina (SL) (125.22 KB - PDF)

View

Suomi (FI) (85.8 KB - PDF)

View

svenska (SV) (87.37 KB - PDF)

View

Product details

Name of medicine
Evant
Active substance
  • Eimeria acervulina, strain 003
  • Eimeria maxima, strain 013
  • Eimeria mitis, strain 006
  • Eimeria praecox, strain 007
  • Eimeria tenella, strain 004
International non-proprietary name (INN) or common name
Coccidiosis vaccine live for chickens
Species
Chicken
Anatomical therapeutic chemical veterinary (ATCvet) code
QI01AN01

Pharmacotherapeutic group

  • Immunologicals for aves
  • Live parasitic vaccines

Therapeutic indication

For the active immunisation of chicks from 1 day of age to reduce intestinal lesions and oocysts output associated with coccidiosis caused by Eimeria acervulina, Eimeria maxima, Eimeria mitis, Eimeria praecox and Eimeria tenella and to reduce clinical signs (diarrhoea) associated with Eimeria acervulina, Eimeria maxima and Eimeria tenella.

Authorisation details

EMA product number
EMEA/V/C/004902
Marketing authorisation holder
Laboratorios Hipra, S.A.

Avda. La Selva, 135
17170 Amer
Girona
Spain

Opinion adopted
07/12/2018
Marketing authorisation issued
05/02/2019
Revision
1

Assessment history

Topics

This page was last updated on

Share this page